Pipeline

ACEA has a robust pipeline of small and large molecules in development for the treatment of cancer and autoimmune diseases. Our lead compound, Abivertinib, for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the EGFR T790M mutation, is currently under review by the China Food and Drug Administration. AC0058, a potential treatment for autoimmune diseases, has entered Phase 1B trial for systemic lupus erythematosus (SLE) in the USA. Also, we have several compounds in preclinical development across multiple cancer settings.

Program & Drug Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Regions

Oncology

Abivertinib

EGFR T790M+(2nd Line)

China

EGFR mut+(1st Line)

China

Lymphomas

China

AC0002

CNS Tumors

Global

AC0078

Pan-TRK inhibitor

Global

ACT01

Multiple oncology indication

Global

ACT02

Multiple oncology indication

Global

ACT03

Multiple oncology indication

Global

ACT04

Multiple oncology indication

Global

Autoimmune Disease

AC0058

SLE

Global